JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers.

JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers. Mol Cancer Ther. 2018 04; 17(4):732-739.

View in: PubMed

subject areas

Animals
Apoptosis
B7-H1 Antigen
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Cell Proliferation
Drug Resistance, Neoplasm
Humans
Janus Kinase 2
Lung Neoplasms
Mice
Mice, Nude
Protein Kinase Inhibitors
Pyrrolidines
Signal Transduction
Sulfonamides
Tumor Cells, Cultured
Xenograft Model Antitumor Assays

authors with profiles

Mitchell C. Posner
Ralph R. Weichselbaum
Sean Pitroda